Risk stratification models and mutational analysis: Keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour

European Journal of Cancer

Volumn 49, Issue 4, 2013, Pages 884-892

  Gronchi, Alessandro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Gastrointestinal stromal tumours; Imatinib; Mutational analysis; Patient selection; Sarcoma

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR;

CANCER PROGNOSIS; CANCER SURGERY; DRUG EFFICACY; EXON; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; TREATMENT RESPONSE; TUMOR VOLUME; WILD TYPE;

EID: 84873728010     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.10.025     Document Type: Article

References (44)

1. P.A. Cassier, F. Ducimetiere, and A. Lurkin A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a European region Br J Cancer 103 2010 165 170
2. R.P. DeMatteo, K.V. Ballman, and C.R. Antonescu Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 373 2009 1097 1104
3. H. Joensuu, M. Eriksson, and H.K. Sundby One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial JAMA 307 2012 1265 1272
4. 4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: soft tissue sarcoma. V.2.2012. Available from: http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp. [accessed September 6, 2012].
5. The ESMO/European Sarcoma Network Working Group Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 23 Suppl 7 2012 vii49 vii55
6. Glivec (imatinib mesylate) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January, 2012.
7. R.P. DeMatteo, J.J. Lewis, D. Leung, S.S. Mudan, J.M. Woodruff, and M.F. Brennan Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 2000 51 58
8. I. Hassan, Y.N. You, and R. Shyyan Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis Ann Surg Oncol 15 2008 52 59
9. B. Nilsson, P. Bumming, and J.M. Meis-Kindblom Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden Cancer 103 2005 821 829
10. C.D. Fletcher, J.J. Berman, and C. Corless Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 2002 459 465
11. M. Miettinen, and J. Lasota Gastrointestinal stromal tumors: pathology and prognosis at different sites Semin Diagn Pathol 23 2006 70 83
12. J.S. Gold, M. Gonen, and A. Gutierrez Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis Lancet Oncol 10 2009 1045 1052
13. S. Rossi, R. Miceli, and L. Messerini Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables Am J Surg Pathol 35 2011 1646 1656
14. H. Joensuu Risk stratification of patients diagnosed with gastrointestinal stromal tumor Hum Pathol 39 2008 1411 1419
15. P. Rutkowski, E. Bylina, and A. Wozniak Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - The impact of tumour rupture on patient outcomes Eur J Surg Oncol 37 2011 890 896
16. S.D. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Green, and A. Trotti AJCC cancer staging handbook 7th ed. 2010 Springer New York
17. H.L. Sobin, and C.H. Wittekind TNM classification of malignant tumors 7th ed. 2012 Wiley-Blackwell Hoboken
18. X. Wang, I. Mori, and W. Tang Helpful parameter for malignant potential of gastrointestinal stromal tumors (GIST) Jpn J Clin Oncol 32 2002 347 351
19. H. Joensuu, A. Vehtari, and J. Riihimaki Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts Lancet Oncol 13 2012 265 274
20. P.A. Cassier, and J.Y. Blay Imatinib mesylate for the treatment of gastrointestinal stromal tumor Expert Rev Anticancer Ther 10 2010 623 634
21. J.F. Emile, S. Brahimi, and J.M. Coindre Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs Med Oncol 29 2012 1765 1772
22. J.A. Laurini, and J.E. Carter Gastrointestinal stromal tumors: a review of the literature Arch Pathol Lab Med 134 2010 134 141
23. C.L. Corless, K.V. Ballman, and C. Antonescu Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001 J Clin Oncol (Meeting Abstracts) 28 2010 10006
24. M. Miettinen, and J. Lasota Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis Arch Pathol Lab Med 130 2006 1466 1478
25. J. Lasota, and M. Miettinen KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs) Semin Diagn Pathol 23 2006 91 102
26. W. El Rifai, M. Sarlomo-Rikala, L.C. Andersson, S. Knuutila, and M. Miettinen DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance Cancer Res 60 2000 3899 3903
27. K.A. Janeway, B. Liegl, and A. Harlow Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors Cancer Res 67 2007 9084 9088
28. J. Andersson, H. Sihto, J.M. Meis-Kindblom, H. Joensuu, N. Nupponen, and L.G. Kindblom NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics Am J Surg Pathol 29 2005 1170 1176
29. C. Mussi, H.U. Schildhaus, A. Gronchi, E. Wardelmann, and P. Hohenberger Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1 Clin Cancer Res 14 2008 4550 4555
30. M. Debiec-Rychter, H. Dumez, and I. Judson Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 40 2004 689 695
31. M. Debiec-Rychter, R. Sciot, and A. Le Cesne KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Eur J Cancer 42 2006 1093 1103
32. M.C. Heinrich, B.P. Rubin, B.J. Longley, and J.A. Fletcher Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations Hum Pathol 33 2002 484 495
33. M.C. Heinrich, K. Owzar, and C.L. Corless Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group J Clin Oncol 26 33 2008 5360 5367
34. M.C. Heinrich, C.L. Corless, and G.D. Demetri Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 2003 4342 4349
35. P. Cassier, E. Fumagalli, and P. Rutkowski Outcome of patients with platelet derived growth factor receptor alpha-mutated GIST in the tyrosine kinase inhibitor era Clin Cancer Res 18 16 2012 4458 4464
36. J. Lasota, and M. Miettinen Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours Histopathology 53 2008 245 266
37. Gastrointestinal Stromal Tumor Meta-Analysis Group (META-GIST) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients J Clin Oncol 28 2010 1247 1253
38. J.A. Carney Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence Mayo Clin Proc 74 1999 543 552
39. C.L. Corless, and M.C. Heinrich Molecular pathobiology of gastrointestinal stromal sarcomas Annu Rev Pathol 3 2008 557 586
40. J. Tsang, I. Rudychev, and S.L. Pescatore Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM) J Clin Oncol (Meeting Abstracts) 24 2006 6119
41. W. Feng, H. Henk, and S. Thomas Compliance and persistency with imatinib J Clin Oncol (Meeting Abstracts) 24 2006 6038
42. L. Noens, V.A.N. Lierde, and M.A De Bock R Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study Blood 113 2009 5401 5411
43. G.D. Demetri, Y. Wang, and E. Wehrle Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors J Clin Oncol 27 2009 3141 3147
44. C. Yoo, M.H. Ryu, and B.W. Kang Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib J Clin Oncol 28 2010 1554 1559